6a7v | pdb_00006a7v

Crystal structure of Mycobacterium tuberculosis VapBC11 toxin-antitoxin complex

spinqualitylabelsall models 6a7v, resolution 1.67Å Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image   Print3D Structural highlights 6a7v is a 8 chain structure with sequence from Mycobacterium tuberculosis H37Rv. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance. Method: X-ray diffraction, Resolution 1.67Å Ligands: 1PE, SO4 Resources: FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT Function VPC11_MYCTU Toxic component of a type II toxin-antitoxin (TA) system. Acts as an RNase. Upon expression in E.coli and M.smegmatis inhibits translation, cell growth and colony formation. Its toxic effects on cell growth and colony formation are neutralized by coexpression with cognate antitoxin VapB11; the effect on translation has not been tested but is probably also neutralized. Publication Abstract from PubMed Toxin-antitoxin (TA) systems are involved in diverse physiological processes in prokaryotes, but their exact role in Mycobacterium tuberculosis (Mtb) virulence and in vivo stress adaptation has not been extensively studied. Here, we demonstrate that the VapBC11 TA module is essential for Mtb to establish infection in guinea pigs. RNA-sequencing revealed that overexpression of VapC11 toxin results in metabolic slowdown, suggesting that modulation of the growth rate is an essential strategy for in vivo survival. Interestingly, overexpression of VapC11 resulted in the upregulation of chromosomal TA genes, suggesting the existence of highly coordinated crosstalk among TA systems. In this study, we also present the crystal structure of the VapBC11 heterooctameric complex at 1.67 A resolution. Binding kinetic studies suggest that the binding affinities of toxin-substrate and toxin-antitoxin interactions are comparable. We used a combination of structural studies, molecular docking, mutational analysis and in vitro ribonuclease assays to enhance our understanding of the mode of substrate recognition by the VapC11 toxin. Furthermore, we have also designed peptide-based inhibitors to target VapC11 ribonuclease activity. Taken together, we propose that the structure-guided design of inhibitors against in vivo essential ribonucleases might be a novel strategy to hasten clearance of intracellular Mtb. Structural, functional and biological insights into the role of Mycobacterium tuberculosis VapBC11 toxin-antitoxin system: targeting a tRNase to tackle mycobacterial adaptation.,Deep A, Tiwari P, Agarwal S, Kaundal S, Kidwai S, Singh R, Thakur KG Nucleic Acids Res. 2018 Nov 30;46(21):11639-11655. doi: 10.1093/nar/gky924. PMID:30329074 From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See Also Ribonuclease 3D structures

Proteopedia Page Contributors and Editors (what is this?)

OCA